BOSTON--(BUSINESS WIRE)--Dr. Jennifer Cermak, PhD, has been appointed as a member of Life Biosciences’ Scientific Advisory Board (SAB), according to an announcement today by Life Biosciences Inc. Dr. Cermak has served as Life Bioscience’s SVP of Clinical Development since the company’s founding.

Dr. Cermak is a serial biotech executive and brings two decades of experience in the research and development of drugs and medical devices. She is responsible for evaluating and leading the development of new drugs and other therapies, working with the leadership of Life Biosciences and its six Daughter companies as they pursue their independent and collaborative research into the eight pathways of age-related decline (ARD).

“We are thrilled and privileged to have Jennifer join the SAB,” said David Sinclair, PhD, AO, co-founder and Scientific Advisor of Life Biosciences. “Her broad-based therapeutic knowledge and proven entrepreneurial acumen are coupled with her remarkably effective leadership to guide our potential acquisitions, portfolio and lead complex programs through significant stages of R&D.” Life Biosciences is the first and largest company to address age-related decline (ARD) as a systemic breakdown of the body, rather than a series of isolated events and conditions.

Throughout her career, Dr. Cermak has demonstrated success co-founding life science companies and quickly building company value, leading all R&D activities. She received her BA in Biology from Boston University, her PhD in Pathology & Laboratory Medicine from Boston University School of Medicine and was a PhD fellow in the Department of Surgery at Harvard Medical School.

Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of LifeLab, its 24,000 square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities; and an emerging AI platform being developed by the company’s Lua subsidiary. Life Biosciences seeks to increase healthspans for everyone, including companion animals.

For more information on Life Biosciences, please visit www.lifebiosciences.com.